Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 11:11:642358.
doi: 10.3389/fcimb.2021.642358. eCollection 2021.

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Ahmed Gamal  1 , Sherman Chu  1   2 , Thomas S McCormick  1 , Katyna Borroto-Esoda  3 , David Angulo  3 , Mahmoud A Ghannoum  1   4
Affiliations
Review

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Ahmed Gamal et al. Front Cell Infect Microbiol. .

Abstract

Systemic infections caused by Candida species are an important cause of morbidity and mortality among immunocompromised and non-immunocompromised patients. In particular, Candida glabrata is an emerging species within the Candida family that causes infections ranging from superficial to life-threatening systemic disease. Echinocandins and azoles are typically the first-line therapies used to treat infections caused by C. glabrata, however, there is an increasing prevalence of resistance to these antifungal agents in patients. Thus, a need exists for novel therapies that demonstrate high efficacy against C. glabrata. Ibrexafungerp is a first-in-class glucan synthase inhibitor with oral availability developed to address this increasing antifungal resistance. Ibrexafungerp demonstrates broad in vitro activity against wild-type, azole-resistant, and echinocandin-resistant C. glabrata species. Furthermore, ibrexafungerp has shown efficacy in low pH environments, which suggests its potential effectiveness in treating vulvovaginal candidiasis. Additional preclinical and clinical studies are needed to further examine the mechanism(s) of ibrexafungerp, including acting as a promising new agent for treating C. glabrata infections.

Keywords: Candida glabrata; antifungal; ibrexafungerp; triterpenoid class (fungerps); ß-(1,3)-D-glucan.

PubMed Disclaimer

Conflict of interest statement

In compliance with the ICMJE uniform disclosure form, all authors declare the following: financial relationships: MG declares that he received funding from Pfizer, Scynexis, Inc., Cidara Therapeutics, and Amplyx Pharmaceuticals. Authors KBE and DA were employed by Scynexis, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. (2020). A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) [Internet]. https://clinicaltrials.gov/ct2/show/record/NCT04029116?term=NCT04029116&....
    1. (2020). A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 With Voriconazole in Patients With Invasive Pulmonary Aspergillosis [Internet]. https://clinicaltrials.gov/ct2/show/record/NCT03672292?term=NCT03672292&....
    1. (2020). Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris [Internet]. https://clinicaltrials.gov/ct2/show/record/NCT03363841?cond=NCT03363841&....
    1. (2020). Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) [Internet]. https://clinicaltrials.gov/ct2/show/record/NCT03059992?term=FURI&draw=2&....
    1. Ahmad A., Khan A. U. (2009). Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur. J. Obstet. Gynecol. Reprod. Biol. 144 (1), 68–71. 10.1016/j.ejogrb.2008.12.020 - DOI - PubMed

Publication types

LinkOut - more resources